Amylyx Pharma Q1 EPS $(0.37), Inline, Cash, Cash Equivalents, And Short-Term Investments Were $279.8M, With Expected Cash Runway into 2028

Benzinga Newsdesk www.benzinga.com Neutral 90.7%